Altered glutamate neurotransmission and behaviour in dementia: Evidence from studies of memantine

Current Molecular Pharmacology

Volumn 2, Issue 1, 2009, Pages 77-82

  Francis, P T ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Agitation; Alzheimer's disease; Glutamate; Neurofibrillary tangles; Tau

Indexed keywords

CHOLINESTERASE INHIBITOR; DIZOCILPINE; GLUTAMIC ACID; GLYCOGEN SYNTHASE KINASE 3; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PHOSPHOPROTEIN PHOSPHATASE 2A; TAU PROTEIN; AMINO ACID RECEPTOR BLOCKING AGENT;

AGGRESSION; AGITATION; ALZHEIMER DISEASE; ANXIETY; ARTICLE; BEHAVIOR DISORDER; CAREGIVER BURDEN; CHOLINERGIC SYSTEM; CINGULATE GYRUS; CLINICAL FEATURE; COGNITION; DELUSION; DEMENTIA; DEPRESSION; DRUG TOLERABILITY; ENZYME ACTIVATION; HUMAN; IRRITABILITY; MOOD DISORDER; NEUROFIBRILLARY TANGLE; NEUROTRANSMISSION; NORADRENERGIC SYSTEM; NURSING HOME; PATIENT SAFETY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PSYCHOSIS; PYRAMIDAL NERVE CELL; QUALITY OF LIFE; SCHIZOPHRENIA; SEROTONINERGIC SYSTEM; SIDE EFFECT; DRUG ANTAGONISM; METABOLISM; REVIEW; SYNAPTIC TRANSMISSION;

DEMENTIA; EXCITATORY AMINO ACID ANTAGONISTS; GLUTAMIC ACID; GLYCOGEN SYNTHASE KINASE 3; HUMANS; MEMANTINE; NEUROFIBRILLARY TANGLES; RECEPTORS, N-METHYL-D-ASPARTATE; SYNAPTIC TRANSMISSION; TAU PROTEINS;

EID: 77449135256     PISSN: 18744672     EISSN: 18744702     Source Type: Journal    
DOI: 10.2174/1874467210902010077     Document Type: Article

References (63)

1. Jost, B. C.; Grossberg, G. T. The evolution of psychiatric symptoms in Alzheimer's disease: a natural history study. J. Am. Geriatr. Soc. 1996, 44(9), 1078-1081.
2. Lopez, O. L.; Becker, J. T.; Sweet, R. A.; Klunk, W.; Kaufer, D. I.; Saxton, J.; Habeych, M.; DeKosky, S. T. Psychiatric symptoms vary with the severity of dementia in probable Alzheimer's disease. J. Neuropsychiatry Clin. Neurosci. 2003, 15(3), 346-353.
3. Potts, H. W.; Richie, M. F.; Kaas, M. J. Resistance to care. J. Gerontol. Nurs. 1996, 22(11), 11-16.
4. Banerjee, S.; Smith, S. C.; Lamping, D. L.; Harwood, R. H.; Foley, B.; Smith, P.; Murray, J.; Prince, M.; Levin, E.; Mann, A.; Knapp, M. Quality of life in dementia: more than just cognition. An analysis of associations with quality of life in dementia. J. Neurol. Neurosurg. Psychiatry 2006, 77(2), 146-148.
5. Georges, J.; Jansen, S.; Jackson, J.; Meyrieux, A.; Sadowska, A.; Selmes, M. Alzheimer's disease in real life - the dementia carer's survey. Int. J. Geriatr. Psychiatry 2008, 23(5), 546-551.
6. Matsumoto, N.; Ikeda, M.; Fukuhara, R.; Shinagawa, S.; Ishikawa, T.; Mori, T.; Toyota, Y.; Matsumoto, T.; Adachi, H.; Hirono, N.; Tanabe, H. Caregiver burden associated with behavioral and psychological symptoms of dementia in elderly people in the local community. Dement. Geriatr. Cogn. Disord. 2007, 23(4), 219-224.
7. Ferris, S. H.; Steinberg, G.; Shulman, E.; Kahn, R. N.; Reisberg, B. Institutionalization of Alzheimer's disease patients: reducing precipitating factors through family counseling. Home Health Care Serv. Q. 1987, 8, 23-51.
8. Yaffe, K.; Fox, P.; Newcomer, R.; Sands, L.; Lindquist, K.; Dane, K.; Covinsky, K. E. Patient and caregiver characteristics and nursing home placement in patients with dementia. JAMA 2002, 287(16), 2090-2097.
9. Cohen-Mansfield, J. Agitated behaviors in the elderly. II. Preliminary results in the cognitively deteriorated. J. Am. Geriatr. Soc. 1986, 34(10), 722-727.
10. McShane, R.; Keene, J.; Gedling, K.; Fairburn, C.; Jacoby, R.; Hope, T. Do neuroleptic drugs hasten cognitive decline in dementia? Prospective study with necropsy follow up. BMJ 1997, 314, 266-270.
11. Ballard, C.; Waite, J. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease. Cochrane Database Syst. Rev. 2006:CD003476.
12. Schneider, L. S.; Dagerman, K. S.; Insel, P. Risk of death with atyipcal antipsychotic drug treatment for dementia. JAMA 2005, 294, 1934-1943.
13. Sink, K. M.; Holden, K. F.; Yaffe, K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA 2005, 293(5), 596-608.
14. Gauthier, S.; Feldman, H.; Hecker, J.; Vellas, B.; Ames, D.; Subbiah, P.; Whalen, E.; Emir, B.; Donepezil MSAD Study Investigators Group. Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease. Int. Psychogeriatr. 2002, 14, 389-404.
15. Howard, R. J.; Juszczak, E.; Ballard, C. G.; Bentham, P.; Brown, R. G.; Bullock, R.; Burns, A. S.; Holmes, C.; Jacoby, R.; Johnson, T.; Knapp, M.; Lindesay, J.; O'Brien, J. T.; Wilcock, G.; Katona, C.; Jones, R. W.; DeCesare, J.; Rodger, M.; CALM-AD Trial Group. Donepezil for the treatment of agitation in Alzheimer's disease. N. Engl. J. Med. 2007, 357(14), 1382-1392.
16. Winblad, B.; Möbius, H. J.; Stöffler, A. Glutamate receptors as a target for Alzheimer's disease - are clinical results supporting the hope? J Neural. Transm. 2002, (Suppl) 62, 217-225.
17. Reisberg, B.; Doody, R.; Stöffler, A.; Schmitt, F.; Ferris, S.; Mobius, H. J.; Memantine Study Group. Memantine in moderate-to-severe Alzheimer's disease. New Engl. J. Med. 2003, 348, 1333-1341.
18. Tariot, P. N.; Farlow, M. R.; Grossberg, G. T.; Graham, S. M.; McDonald, S.; Gergel, I.; Memantine Study Group. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil. A randomized controlled trial. JAMA 2004, 291(3), 317-324.
19. European Medicines Evaluation Agency. Ebixa EPAR, CHMP Variation Assessment Report. Scientific Discussion. November 2005.
20. Cummings, J. L.; Mega, M.; Gray, K.; Rosenberg-Thompson, S.; Carusi, D. A.; Gornbein, J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994, 44, 2308-2314.
21. Cummings, J. L. The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology 1997, 48(5 Suppl 6), S10-S16.
22. Gauthier, S.; Wirth, Y.; Möbius, H. J. Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies. Int. J. Geriatr. Psychiatry 2005, 20(5), 459-464.
23. Gauthier, S.; Loft, H.; Cummings, J. Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis. Int. J. Geriatr. Psychiatry 2008, 23(5), 537-545.
24. Cummings, J. L.; Schneider, E.; Tariot, P. N.; Graham, S. M. Behavioural effects of memantine in Alzheimer's disease patients receiving donepezil treatment. Neurology 2006, 67, 57-63.
25. Wilcock, G. K.; Ballard, C. G.; Cooper, J. A.; Loft, H. Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies. J. Clin. Psychiatry 2008, 69(3), 341-348.
26. McShane, R.; Areosa Sastre, A.; Minakaran, N. Memantine for dementia. Cochrane Database Syst. Rev. 2006, 2, CD003154.
27. Danbolt, N. C. Glutamate uptake. Prog. Neurobiol. 2001, 65(1), 1-105.
28. Francis, P. T.; Sims, N. R.; Procter, A. W.; Bowen, D. M. Cortical pyramidal neurone loss may cause glutamatergic hypoactivity and cognitive impairment in Alzheimer's disease: investigative and therapeutic perspectives. J. Neuro-chem. 1993, 60(5), 1589-1604.
29. Francis, P. T. The interplay of neurotransmitters in Alzheimer's disease. CNS Spectr. 2005, 10, 6-9.
30. Kirvell, S. L.; Esiri, M.; Francis, P. T. Down-regulation of vesicular glutamate transporters precedes cell loss and pathology in Alzheimer's disease. J. Neurochem. 2006, 98(3), 939-950.
31. Tamminga, C. A. Schizophrenia and glutamatergic transmission. Crit. Rev. Neurobiol. 1998, 12(1-2), 21-36.
32. Laruelle, M.; Frankle, W. G.; Narendran, R.; Kegeles, L. S.; Abi-Dargham, A. Mechanism of action of antipsychotic drugs: from dopamine D(2) receptor antagonism to glutamate NMDA facilitation. Clin. Ther. 2005, 27(Suppl A), S16-S24.
33. Paul, I. A.; Skolnick, P. Glutamate and depression: clinical and preclinical studies. Ann. N Y Acad. Sci. 2003, 1003, 250-272.
34. Olivier, B.; van Oorschot, R. 5-HT1B receptors and aggression: a review. Eur. J. Pharmacol. 2005, 526(1-3), 207-217.
35. Tekin, S.; Mega, M. S.; Masterman, D. M.; Chow, T.; Garakian, J.; Vinters, H. V.; Cummings, J. L. Orbitofrontal and anterior cingulate cortex neurofibrillary tangle burden is associated with agitation in Alzheimer disease. Ann. Neurol. 2001, 49, 355-361.
36. Parsons, C. G.; Danysz, W.; Quack, G. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist - a review of preclinical data. Neuropharmacology 1999, 38, 735-767.
37. Parsons, C. G.; Stöffler, A.; Danysz, W. Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system - too little activation is bad, too much is even worse. Neuropharmacology 2007, 53(6), 699-723.
38. Danysz, W.; Parsons, C. G.; Mobius, H. J.; Stoffler, A.; Quack, G. Neuroprotective and symptomatological action of memantine relevant for Alzheimer's disease - a unified glutamatergic hypothesis on the mechanism of action. Neurotox. Res. 2000, 2(2-3), 85-97.
39. Parsons, C. G.; Gruner, R.; Rozental, J.; Millar, J.; Lodge, D. Patch clamp studies on the kinetics and selectivity of N-methyl-D-aspartate receptor antagonism by memantine (1-amino-3,5-dimethyladamantan). Neuropharmacology 1993, 32(12), 1337-1350.
40. Snyder, E. M.; Nong, Y.; Almeida, C. G.; Paul, S.; Moran, T.; Choi, E. Y.; Nairn, A. C.; Salter, M. W.; Lombroso, P. J.; Gouras, G. K.; Greengard, P. Regulation of NMDA receptor trafficking by amyloid-beta. Nat. Neurosci. 2005, 8, 1051-1058.
41. Senanarong, V.; Cummings, J. L.; Fairbanks, L.; Mega, M.; Masterman, D. M.; O'Connor, S. M.; Strickland, T. L. Agitation in Alzheimer's disease is a manifestation of frontal lobe dysfunction. Dement. Geriatr. Cogn. Disord. 2004, 17, 14-20.
42. Danysz, W.; Zajaczkowski, W.; Parsons, C. G. Modulation of learning processes by ionotropic glutamate receptor ligands. Behav. Pharmacol. 1995, 6, 455-474.
43. Bliss, T. V.; Collingridge, G. L. A synaptic model of memory: long-term potentiation in the hippocampus. Nature 1993, 361(6407), 31-39.
44. Lynch, G. Memory and the brain: unexpected chemistries and a new pharmacology. Neurobiol. Learn. Mem. 1998, 70(1-2), 82-100.
45. Francis, P. T. Glutamatergic systems in Alzheimer's disease. Int. J Geriatr. Psychiatry 2003, 18(Suppl 1), S15-S21.
46. Procter, A. W.; Francis, P. T.; Holmes, C.; Webster, M.-T.; Qume, M.; Stratmann, G. C.; Doshi, R.; Mann, D. M. A.; Harrison, P. J.; Pearson, R. C. A.; Bowen, D. M. beta-Amyloid precursor protein isoforms show correlations with neurones but not with glia of demented subjects. Acta Neuropathol. (Berl.) 1994, 88(6), 545-552.
47. Lovell, M. A.; Ehmann, W. D.; Mattson, M. P.; Markesbery, W. R. Elevated 4-hydroxynonenal in ventricular fluid in Alzheimer's disease. Neurobiol. Aging 1997, 18(5), 457-461.
48. Begni, B.; Brighina, L.; Sirtori, E.; Fumagalli, L.; Andreoni, S.; Beretta, S.; Oster, T.; Malaplate-Armand, C.; Isella, V.; Appollonio, I.; Ferrarese, C. Oxidative stress impairs glutamate uptake in fibroblasts from patients with Alzheimer's disease. Free Radic. Biol. Med. 2004, 37(6), 892-901.
49. Cacabelos, R.; Takeda, M.; Winblad, B. The glutamatergic system and neurodegeneration in dementia: preventive strategies in Alzheimer's disease. Int. J. Geriatr. Psychiatry 1999, 14(1), 3-47.
50. Klyubin, I.; Walsh, D. M.; Cullen, W. K.; Fadeeva, J. V.; Anwyl, R.; Selkoe, D. J.; Rowan, M. J. Soluble Arctic amyloid beta protein inhibits hippocampal long-term potentiation in vivo. Eur. J. Neurosci 2004, 19, 2839-2846.
51. Abbott, J. J.; Howlett, D. R.; Francis, P. T.; Williams, R. J. Abeta(1-42) modulation of Akt phosphorylation via alpha7 nAChR and NMDA receptors. Neurobiol. Aging 2007, 29(7), 992-1001.
52. Bachman, D.; Rabins, P. "Sundowning" and other temporally associated agitation states in dementia patients. Annu. Rev. Med. 2006, 57, 499-511.
53. Neilsen, H. S.; Georg, B.; Hannibal, J.; Fahrenkrug, J. Homer-1 mRNA in the rat suprachiasmatic nucleus is regulated differentially by the retinohypothalamic tract transmitters pituitary adenylate cyclase activating polypeptide and glutamate at time points where light phase-shifts the endogenous rhythm. Brain Res. Mol. Brain Res. 2002, 105, 79-85.
54. Li, L.; Sengupta, A.; Haque, N.; Grundke-Iqbal, I.; Iqbal, K. Memantine inhibits and reverses the Alzheimer type abnormal hyperphosphorylation of tau and associated neurodegeneration. FEBS Lett. 2004, 566, 261-269.
55. Grimes, C. A.; Jope, R. S. The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog. Neurobiol. 2001, 65(4), 391-426.
56. De Sarno, P.; Bijur, G. N.; Zmijewska, A. A.; Li, X.; Jope, R. S. In vivo regulation of GSK3 phosphorylation by cholinergic and NMDA receptors. Neurobiol. Aging 2006, 27, 413-422.
57. Chan, S. F.; Sucher, N. J. An NMDA receptor signaling complex with protein phosphatase 2A. J. Neurosci. 2001, 21, 7985-7992.
58. Capsoni, S.; Ugolini, G.; Comparini, A.; Ruberti, F.; Berardi, N.; Cattaneo, A. Alzheimer-like neurodegeneration in aged antinerve growth factor transgenic mice. Proc. Natl. Acad. Sci. USA 2000, 97(12), 6826-6831.
59. Ruberti, F.; Capsoni, S.; Comparini, A.; Di Daniel, E.; Franzot, J.; Gonfloni, S.; Rossi, G.; Berardi, N.; Cattaneo, A. Phenotypic knockout of nerve growth factor in adult transgenic mice reveals severe deficits in basal forebrain cholinergic neurons, cell death in the spleen, and skeletal muscle dystrophy. J. Neurosci. 2000, 20(7), 2589-2601.
60. Capsoni, S.; Giannotta, S.; Cattaneo, A. Early events of Alzheimer-like neurodegeneration in anti-nerve growth factor transgenic mice. Brain Aging 2002, 2(4), 24-43.
61. Chohan, M. O.; Khatoon, S.; Iqbal, I. -G.; Iqbal, K. Involvement of I2PP2A in the abnormal hyperphosphorylation of tau and its reversal by memantine. FEBS Lett. 2006, 580, 3973-3979.
62. Degerman Gunnarsson, M.; Kilander, L.; Basun, H.; Lannfelt, L. Reduction of phosphorylated tau during memantine treatment of Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 2007, 24, 247-252.
63. Volavka, J.; Citrome, L.; Huertas, D. Update on the biological treatment of aggression. Actas Esp. Psiquiatr. 2006, 34(2), 123-135.